Adaptive Biotechnologies Corporation (ADPT) Ownership
ADPT ownership summary
as of October 18, 2026- Institutions
- 99.2% of shares outstanding
- Insiders
- 1.29% of shares outstanding
- Shares outstanding
- 159.6M
- Float
- 125.5M shares available to trade
- Short interest
- 9.38% 11.8M shares short
- Days to cover
- 5.27 short interest down 12.2% vs prior month
- Institutions 99.15%
- Insiders 1.29%
ADPT top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Viking Global Investors LP | 4.70% | 30.0M | $720.4M | — | June 30, 2026 |
| 2 | BlackRock Inc | 2.37% | 15.1M | $363.6M | +1.8M (+13.8%) | June 30, 2026 |
| 3 | Vanguard Capital Management, LLC | 1.00% | 6.4M | $153.8M | +309,443 (+5.1%) | June 30, 2026 |
| 4 | Wellington Management Company LLP | 0.93% | 5.9M | $142.0M | +2.1M (+53.2%) | June 30, 2026 |
| 5 | Vanguard Portfolio Management, LLC | 0.86% | 5.5M | $131.5M | +984,757 (+21.9%) | June 30, 2026 |
| 6 | D. E. Shaw & Co LP | 0.72% | 4.6M | $111.1M | +2.7M (+135.3%) | June 30, 2026 |
| 7 | Westfield Capital Management Company, L.P. | 0.67% | 4.3M | $102.5M | −1.2M (−21.5%) | June 30, 2026 |
| 8 | Geode Capital Management, LLC | 0.57% | 3.6M | $87.5M | +5,783 (+0.2%) | June 30, 2026 |
| 9 | State Street Corp | 0.54% | 3.5M | $83.1M | +231,143 (+7.2%) | June 30, 2026 |
| 10 | Amvescap Plc. | 0.48% | 3.1M | $74.3M | −1.4M (−30.5%) | June 30, 2026 |
| 11 | The Goldman Sachs Group Inc | 0.47% | 3.0M | $71.7M | −257,850 (−8.0%) | June 30, 2026 |
| 12 | T. Rowe Price Associates, Inc. | 0.42% | 2.7M | $64.0M | +1.1M (+70.2%) | June 30, 2026 |
| 13 | Driehaus Capital Management LLC | 0.40% | 2.5M | $60.7M | +777,102 (+44.4%) | June 30, 2026 |
| 14 | Arrowstreet Capital Limited Partnership | 0.40% | 2.5M | $60.6M | +529,418 (+26.5%) | June 30, 2026 |
| 15 | Lord, Abbett & Co LLC | 0.39% | 2.5M | $59.4M | −1.1M (−30.0%) | June 30, 2026 |
| 16 | Nuveen, LLC | 0.37% | 2.4M | $56.8M | +1.1M (+81.4%) | June 30, 2026 |
| 17 | BNP Paribas Investment Partners SA | 0.34% | 2.2M | $52.4M | −505,755 (−18.8%) | June 30, 2026 |
| 18 | Fred Alger Management, LLC | 0.33% | 2.1M | $50.3M | +29,138 (+1.4%) | June 30, 2026 |
| 19 | ARK Investment Management LLC | 0.33% | 2.1M | $50.2M | −2,663 (−0.1%) | June 30, 2026 |
| 20 | Delaware Management Holdings Inc | 0.30% | 1.9M | $45.4M | +8,005 (+0.4%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 11.6M shares and 6 cut 4.4M.
ADPT top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 3.04% | 4.8M | $116.4M | −6,635 (−0.1%) | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 2.58% | 4.1M | $99.0M | −47,488 (−1.1%) | September 30, 2026 |
| 3 | ARK Genomic Revolution ETF | 1.13% | 1.8M | $43.2M | +4,398 (+0.2%) | September 30, 2026 |
| 4 | Vanguard Small Cap Index | 1.10% | 1.7M | $42.0M | −1,683 (−0.1%) | August 31, 2026 |
| 5 | Fidelity Small Cap Index | 1.06% | 1.7M | $40.5M | +14,628 (+0.9%) | July 31, 2026 |
| 6 | Xtrackers MSCI World Swap ETF 1C | 1.00% | 1.6M | $38.2M | −10,014 (−0.6%) | December 31, 2025 |
| 7 | Alger Small Cap Focus I | 0.94% | 1.5M | $35.9M | — | July 31, 2026 |
| 8 | iShares Russell 2000 Growth ETF | 0.93% | 1.5M | $35.7M | −1,883 (−0.1%) | September 30, 2026 |
| 9 | Oberweis Micro-Cap | 0.76% | 1.2M | $29.2M | +441,000 (+56.9%) | June 30, 2026 |
| 10 | iShares Biotechnology ETF | 0.76% | 1.2M | $29.0M | −9,152 (−0.8%) | September 30, 2026 |
| 11 | Lord Abbett Developing Growth A | 0.75% | 1.2M | $28.7M | +59,591 (+5.3%) | July 31, 2026 |
| 12 | T. Rowe Price Small-Cap Stock | 0.74% | 1.2M | $28.4M | +217,996 (+22.6%) | August 31, 2026 |
| 13 | Invesco Main Street Small Cap R6 | 0.70% | 1.1M | $27.0M | — | August 31, 2026 |
| 14 | T. Rowe Price Integrated US Sm Gr Eq | 0.69% | 1.1M | $26.5M | — | August 31, 2026 |
| 15 | BNP Paribas US Small Cap ClassicC | 0.67% | 1.1M | $25.6M | −2,044 (−0.2%) | August 31, 2026 |
| 16 | BNP Paribas Health Cr Innovtr Cl Cap | 0.63% | 1.0M | $24.3M | −184 (−0.0%) | August 31, 2026 |
| 17 | Vanguard MStar Small Cap Growth Indx Inv | 0.63% | 1.0M | $24.1M | −8,662 (−0.9%) | August 31, 2026 |
| 18 | Vanguard Explorer Inv | 0.62% | 994K | $23.9M | +630,469 (+173.5%) | June 30, 2026 |
| 19 | T. Rowe Price New Horizons | 0.60% | 959K | $23.0M | +435,508 (+83.2%) | August 31, 2026 |
| 20 | Harbor Small Cap Growth Instl | 0.60% | 952K | $22.9M | −192,940 (−16.9%) | June 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ADPT insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-24 | Julie Rubinstein | Sell | $14.02 | 19,060 | $267,221 |
| 2026-04-22 | Julie Rubinstein | Sell | $14.13 | 19,060 | $269,318 |
| 2026-04-21 | Julie Rubinstein | Sell | $14.66 | 30,941 | $453,595 |
| 2026-04-20 | Julie Rubinstein | Sell | $14.55 | 19,060 | $277,323 |
| 2026-04-16 | Julie Rubinstein | Sell | $14.18 | 19,060 | $270,271 |
| 2026-04-13 | Julie Rubinstein | Sell | $13.15 | 19,060 | $250,639 |
| 2026-04-10 | Julie Rubinstein | Sell | $12.77 | 19,060 | $243,396 |
| 2026-04-08 | Julie Rubinstein | Sell | $14.83 | 30,941 | $458,855 |
| 2026-04-08 | Harlan S Robins | Sell | $14.85 | 10,000 | $148,500 |
| 2026-04-08 | Francis Lo | Sell | $15.07 | 22,564 | $340,039 |
| 2026-04-08 | Chad M Robins | Sell | $15.19 | 37,263 | $566,025 |
| 2026-04-07 | Julie Rubinstein | Sell | $13.56 | 19,060 | $258,454 |
| 2026-04-06 | Chad M Robins | Sell | $14.41 | 83,332 | $1.2M |
| 2026-04-01 | Julie Rubinstein | Sell | $14.45 | 19,060 | $275,417 |
| 2026-03-23 | Julie Rubinstein | Sell | $13.83 | 19,060 | $263,600 |
| 2026-03-20 | Julie Rubinstein | Sell | $13.37 | 19,060 | $254,832 |
| 2026-03-18 | Julie Rubinstein | Sell | $13.18 | 19,060 | $251,211 |
| 2026-03-16 | Julie Rubinstein | Sell | $13.41 | 19,060 | $255,595 |
| 2026-03-13 | Julie Rubinstein | Sell | $12.96 | 19,060 | $247,018 |
| 2026-03-11 | Chad M Robins | Sell | $13.17 | 470,167 | $6.2M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ADPT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ADPT
Institutional investors own 99.2% of Adaptive Biotechnologies's shares and insiders 1.29%. The largest holder is Viking Global Investors LP with 4.70% of the shares (30.0M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 6 reduced their stake in the latest filings. Short interest is 9.38% of the float, or 5.27 days of average trading volume. The share count rose 1,176.1% since 2017.
Related: ADPT analyst forecast, ADPT key metrics. See the ADPT stock overview for the latest quote and news.
ADPT ownership FAQ
Who owns the most Adaptive Biotechnologies stock?
The largest shareholders of Adaptive Biotechnologies are Viking Global Investors LP (4.70%), BlackRock Inc (2.37%), Vanguard Capital Management, LLC (1.00%), Wellington Management Company LLP (0.93%), Vanguard Portfolio Management, LLC (0.86%).
What percentage of Adaptive Biotechnologies is owned by institutions?
Institutions hold 99.2% of Adaptive Biotechnologies's shares outstanding; insiders hold 1.29%.
Which funds own Adaptive Biotechnologies?
The largest fund holders of Adaptive Biotechnologies are Vanguard MStar Total Stk Mkt Idx Invest (3.04%), iShares Russell 2000 ETF (2.58%), ARK Genomic Revolution ETF (1.13%), Vanguard Small Cap Index (1.10%), Fidelity Small Cap Index (1.06%).
What is Adaptive Biotechnologies's short interest?
11.8M shares of Adaptive Biotechnologies were sold short, 9.38% of the float; at the average daily volume it would take 5.27 days to cover.
Are insiders buying or selling Adaptive Biotechnologies?
Of the latest 20 reported insider transactions in Adaptive Biotechnologies (since March 11, 2026), 0 were purchases and 20 were sales.
How many shares of Adaptive Biotechnologies are outstanding?
Adaptive Biotechnologies has 159.6M shares outstanding, of which 125.5M are in the public float.